Caris Life Sciences Inc (CAI)

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer SeekMay 15, 2026 8:30 AM
PR Newswire (US) The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris-led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified biomarkers may miss newly approved treatment opportunities, while clinicians face increasing challenges staying current with evolving evidence.Since 2014, Caris patients have benefited from the dynamic Caris Lookback Program, which addresses limitations of static molecular profiling reports. Through this program, Caris continuously monitors new FDA approvals and guideline updates regarding biomarker-linked therapies.  When new clinical actionability is identified, Caris retrospectively reviews prior patient test results to identify those patients whose molecular profiles align with the new or updated recommendations, all without the need for additional testing. Treating oncologists are then proactively notified through coordinated Medical Affairs and Molecular Science Liaison (MSL) outreach. Caris patients can therefore benefit long after testing has occurred and oncologists can benefit from updated therapeutic insights."As the number of biomarker-driven therapies continues to accelerate, a static analysis limited to a single moment-in-time is no longer sufficient in many cases," said James Hamrick, MD, MPH, Chairman, Caris Precision Oncology Alliance. "The Caris Lookback Program was designed to extend the clinical value of comprehensive molecular profiling over time by continuously reviewing prior results through the lens of newly emerging therapeutic evidence, helping ensure that patients and their physicians can benefit from ongoing advances in precision oncology."In this large real-world analysis, Caris evaluated 87 biomarker-directed FDA approvals between 2018 and 2025 using a structured clinical impact framework. Approximately one-third of these approvals met criteria for inclusion in the Caris Lookback Program based on their potential clinical value and actionability. From a database of more than 483,000 molecular profiles, the program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types and multiple tumor-agnostic indications.The program's impact spanned a broad range of solid tumors, including non-small cell lung, breast, colorectal and pancreatic cancers, with non-small cell lung cancer accounting for approximately 40% of identified opportunities. The study also underscored the importance of multi-modal profiling, as biomarker detection required diverse methodologies, including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), Immunohistochemistry (IHC) and combinations of these approaches.Beyond molecular identification, the study also demonstrated the effectiveness of proactive clinical engagement. By integrating comprehensive molecular profiling with continuous evidence surveillance and targeted physician engagement, the Caris Lookback Program demonstrates how a single comprehensive test can deliver dynamic, longitudinal clinical utility, helping identify patients who may benefit from newly approved therapies without repeat biopsies or additional testing.MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients (ages 1+).About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project,"  "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.   You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-on-the-caris-lookback-program-demonstrating-the-ongoing-clinical-value-of-comprehensive-testing-with-caris-mi-cancer-seek-302773279.htmlSOURCE Caris Life Sciences Original: Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene PanelsMay 11, 2026 12:15 PM
PR Newswire (US) Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determinationIRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab. These findings highlight the importance of testing all cancer patients with ultra-deep WES, the only truly comprehensive genomic profile for therapy selection. The study used Caris' large-scale, real-world clinico-genomic database, containing 26,756 patients treated with pembrolizumab who were evaluable for this study. WES provides a true measurement of TMB by interrogating every protein-coding gene mutation that may create a neoantigen, in comparison to targeted panels that only estimate TMB with incomplete gene coverage.Key findings include:The analysis compared WES-measured TMB with commercially available targeted panel estimates of TMB and found discordance in 10-15% of cases, with error rates correlating to panel size.In discordant cases, WES TMB more accurately predicted overall survival in pembrolizumab-treated patients than panel-based estimates.In a subset of 'TMB reliant' patients (n = 3,981), for example, patients with tumor types that lack disease-specific immune checkpoint inhibitor indications, the median overall survival in discordant cases was about five months longer for WES TMB-High and panel TMB-Low compared to WES TMB-Low and panel TMB-High cases treated with pembrolizumab."These findings underscore the critical importance of using Whole Exome Sequencing to guide immunotherapy decisions," said Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer at Caris. "Whole Exome Sequencing is the gold-standard for determination of tumor mutational burden, ensuring that patients who stand to benefit from pembrolizumab are correctly identified and that those unlikely to respond are not exposed to unnecessary treatment."The study concludes that WES-based TMB measurements are a superior predictor of pembrolizumab benefit than panel-based TMB estimates and more reliably identify both patients who may benefit from therapy and those unlikely to respond, particularly in tumor types where TMB is the primary biomarker guiding access to immune checkpoint inhibitors.Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors and includes quantitative reporting of TMB.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.?? You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-whole-exome-measurement-of-tumor-mutational-burden-results-in-increased-overall-survival-compared-to-estimates-from-targeted-gene-panels-302768392.htmlSOURCE Caris Life Sciences Original: Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing AuthorizationMay 8, 2026 4:05 PM
PR Newswire (US) IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood-based molecular profiling test, on specimens originating from New York State. Caris Assure is a blood-based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality systems, personnel qualifications and compliance with applicable state regulations."Caris is committed to meeting the highest standards for laboratory quality, validation and regulatory compliance," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "This submission of Caris Assure for review through the New York State Department of Health's Wadsworth Center reflects our disciplined approach to expanding access to our technologies in a manner that demonstrates the rigor, responsibility and focus on the patient that define Caris Life Sciences and guide our work in the markets we serve."At this time, no determination has been made by NYSDOH, and Caris Assure is not authorized for use on blood-based specimens originating from New York State unless and until CLEP authorization is granted.Caris operates a CAP-accredited, CLIA-certified clinical laboratory and performs testing in jurisdictions where it is authorized to do so, in accordance with all applicable federal, state, and local regulations. Any future availability of Caris Assure in New York State will be contingent upon completion of the CLEP review process administered by the Wadsworth Center and receipt of the appropriate authorization.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking StatementsThis press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606  View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-submits-application-to-new-york-state-department-of-health-for-caris-assure-bloodbased-testing-authorization-302767104.htmlSOURCE Caris Life Sciences Original: Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization

Caris Life Sciences Reports First Quarter 2026 Financial ResultsMay 7, 2026 4:05 PM
PR Newswire (US) Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corresponding prior year period, consisting of approximately 43,600 MI Profile cases and approximately 9,200 Caris Assure cases.Reported gross margin of 65%, an approximate 1,800 bps improvement over the corresponding prior year period.Reported net loss of $0.5 million.Reported positive Adjusted EBITDA of $26.2 million.Reported positive net cash provided by operating activities of $32.9 million, and positive free cash flow of $22.5 million, inclusive of annual bonus payments of $30.5 million."We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. "We are also encouraged by the Achieve 1 data, including the blinded readout, which demonstrates the superior performance of our whole genome technology over inferior techniques such as methylation. We remain focused on strengthening Caris Detect through the incorporation of additional pillars in advance of our upcoming launch."Recent Operating HighlightsRe-aligned sales force in January 2026, and exited at a quarterly run-rate of approximately 56,000 completed cases for February and March.Reported Achieve 1 study results reinforcing the superior sensitivity and specificity of Caris Detect.Launched and received MolDX approval for Caris ChromoSeq, Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies.Launched Caris MI Clarity next-generation prognostic tool that leverages multimodal AI technology and computational pathology to deliver rapid, clinically actionable results for HR+/HER2-, postmenopausal, node-negative early-stage breast cancer patients.Powered by comprehensive approach of whole exome and whole transcriptome, launched the following new Caris AI Insights:Guiding first-line therapy selection and treatment de-escalation in pancreatic cancerIdentifying early platinum resistance in ovarian cancerIdentifying the benefit or harm from the addition of chemotherapy for NSCLC patientsSurpassed 1,070,000 total profiles and 790,000 total matched profiles through March 31, 2026.More than 677,000 whole exome and 728,000 whole transcriptome pro?les through March 31, 2026.Refinanced $400 million credit facility at a lower borrowing cost and secured access to additional strategic capital from Blue Owl and Blackstone.First Quarter 2026 Financial ResultsTotal revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%.The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions.Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively.Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of $21.1 million, or 18%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.Net loss was $0.5 million for the three months ended March 31, 2026, as compared to a net loss of $102.6 million for the three months ended March 31, 2025. Net loss per share attributable to common shareholders, basic and diluted, was $0.00 for the three months ended March 31, 2026, as compared to a net loss per share attributable to common shareholders, basic and diluted, of $3.57 for the three months ended March 31, 2025.Net cash provided by operating activities was $32.9 million for the three months ended March 31, 2026, as compared to net cash used in operating activities of $31.3 million for the three months ended March 31, 2025, a 205% improvement. The improvement was driven by improved reimbursement from molecular profiling services.2026 Financial Outlook and GuidanceCaris Life Sciences reaffirms its guidance for full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing growth of 23% to 26% compared to full year 2025 and reaffirms its guidance to clinical therapy selection volume growth of approximately 20% compared to full year 2025.Conference Call InformationEvent:                          Caris First Quarter 2026 Financial Results Conference Call
Date:                            Thursday, May 7, 2026
Time:                            3:30 p.m. CT (4:30 p.m. ET)
Webcast Link:              https://edge.media-server.com/mmc/p/6iwr2xf8/Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call. A replay of the conference call will be available on our investor relations website shortly after the conclusion of the call.About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.We intend to use the investor page of our website, https://investor.carislifesciences.com, as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases, SEC filings, public conference calls and webcasts.Forward-Looking StatementsThis press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: technical, operational and implementation requirements the failure of which affect the timing of or prevent commercialization of Caris Detect; future performance and clinical utility of Caris Detect; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Non-GAAP MeasuresWe use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States ("GAAP"), to supplement our condensed consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges.We define free cash flow as net cash provided by (used in) operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash.A reconciliation of the non-GAAP financial measures used in this press release to the respective comparable GAAP financial measures, can be found below.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606Investor Relations:
IR@CarisLS.com
917.689.3511Caris Life Sciences, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(unaudited) 
(amounts in thousands, except share and per share data)Three Months Ended March 31,
2026
2025



Revenue:


Molecular profiling services$             210,800
$             114,081Pharma research and development services5,374
6,834Total revenue216,174
120,915Costs and operating expenses:


Cost of Services - Molecular profiling services72,884
60,894Cost of Services - Pharma research and development services1,942
2,958Selling and marketing expense45,043
39,829General and administrative expense59,708
52,119Research and development expense31,315
23,066Total costs and operating expenses210,892
178,867Income (Loss) from operations5,282
(57,952)Other expense, net:


Interest income6,834
503Interest expense(12,809)
(12,782)Changes in fair value of financial instruments—
(32,333)Other income (expense), net49
(17)Total other expense, net(5,926)
(44,629)Loss before income taxes and income tax benefit(644)
(102,581)Income tax benefit134
—Net loss(510)
(102,581)Other comprehensive income (loss), net of tax:


Foreign currency translation adjustments(43)
35Comprehensive loss(553)
(102,546)



Net loss attributable to common shareholders:


Net loss(510)
(102,581)Adjustments of redeemable convertible preferred stock to redemption value—
(24,462)Net loss attributable to common shareholders$                 (510)
$            (127,043)Net loss per share attributable to common shareholders, basic and diluted$                  0.00
$                 (3.57)Weighted-average shares used in computing net loss per share attributable
to common shareholders, basic and diluted282,562,013
35,623,042 Caris Life Sciences, Inc.Condensed Consolidated Balance Sheets (unaudited) 
(amounts in thousands, except share data)As of March 31,
As of December 31,
2026
2025



Assets


Current assets:


Cash, cash equivalents, and restricted cash$             821,147
$             797,799Short-term marketable securities2,315
2,295Accounts receivable90,517
112,140Supplies76,289
63,625Prepaid expenses and other current assets23,912
21,941Total current assets1,014,180
997,800Property and equipment, net82,669
63,170Goodwill19,344
19,344Other assets46,195
45,349Total assets$           1,162,388
$           1,125,663Liabilities and Shareholders' Equity


Current liabilities:


Accounts payable$              69,802
$              39,206Accrued expenses and other current liabilities73,921
87,770Current portion of indebtedness173
169Total current liabilities143,896
127,145Long-term indebtedness, net of debt discounts381,402
378,823Other long-term liabilities43,600
42,388Total liabilities568,898
548,356Commitments and contingencies


Shareholders' equity:


Preferred stock, $0.001 par value per share; 100,000,000 shares
authorized as of March 31, 2026 and December 31, 2025; no shares
issued and outstanding as of March 31, 2026 and December 31, 2025—
—Common stock, $0.001 par value per share; 2,800,000,000 shares
authorized as of March 31, 2026 and December 31, 2025; 284,262,436
and 284,137,810 shares issued as of March 31, 2026 and December 31,
2025, respectively; 282,650,723 and 282,526,097 shares outstanding as
of March 31, 2026 and December 31, 2025, respectively; shares issued
and outstanding include 23,446 unvested shares subject to repurchase
as of March 31, 2026 and December 31, 2025284
283Treasury stock at cost, 1,611,713 shares of common stock as of
March 31, 2026 and December 31, 2025(16,896)
(16,896)Additional paid-in capital3,158,455
3,141,720Accumulated deficit(2,549,246)
(2,548,736)Accumulated other comprehensive income893
936Total shareholders' equity593,490
577,307Total liabilities and shareholders' equity$           1,162,388
$           1,125,663 Caris Life Sciences, Inc.Condensed Consolidated Statement of Cash Flows(unaudited) 
(amounts in thousands)Three Months Ended March 31,
2026
2025



Cash flows from operating activities


Net loss$                 (510)
$            (102,581)Adjustments to reconcile net loss to net cash used in operating activities:


Depreciation and amortization5,065
7,045Stock-based compensation expense15,872
14,691Non-cash operating lease expense1,323
1,452Amortization of debt discounts2,624
1,945Changes in fair value of financial instruments—
32,333Other214
456Changes in operating assets and liabilities:


Accounts receivable21,623
7,913Supplies(13,328)
2,061Prepaid expenses and other current assets(1,554)
2,470Other assets153
36Accounts payable16,371
(1,739)Accrued expenses and other liabilities(14,977)
2,580Net cash provided by (used in) operating activities32,876
(31,338)



Cash flows from investing activities


Purchases of property and equipment(10,342)
(2,689)Net cash used in investing activities(10,342)
(2,689)



Cash flows from financing activities


Payments made on finance lease obligations(40)
(22)Proceeds from exercise of stock options920
1,434Payment of taxes withheld from net settlement of exercised options (56)
—Payment of deferred offering costs—
(105)Repurchase of common stock—
(22)Net cash provided by financing activities824
1,285



Effect of exchange rate changes on cash, cash equivalents, and restricted (10)
4Net increase (decrease) in cash, cash equivalents, and restricted cash23,348
(32,738)



Cash, cash equivalents, and restricted cash at beginning of period800,042
68,028Cash, cash equivalents, and restricted cash at end of period$             823,390
$              35,290 Reconciliation of GAAP Net Loss to Adjusted EBITDA(unaudited) 
(amounts in thousands)Three Months Ended March 31,
2026
2025



Net loss$                 (510)
$            (102,581)Interest income(6,834)
(503)Interest expense12,809
12,782Changes in fair value of financial instruments—
32,333Other income (expense), net(49)
17Income tax benefit(134)
—Depreciation and amortization expense5,065
7,045Stock-based compensation expense15,872
14,691Adjusted EBITDA$              26,219
$             (36,216) Reconciliation of Net Cash Provided by (Used in) Operating Activities to Free Cash Flow(unaudited) 
(amounts in thousands)Three Months Ended March 31,
2026
2025



Net cash provided by (used in) operating activities$              32,876
$             (31,338)Less: purchases of property and equipment(10,342)
(2,689)Free cash flow$              22,534
$             (34,027)  View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-reports-first-quarter-2026-financial-results-302766055.htmlSOURCE Caris Life Sciences Original: Caris Life Sciences Reports First Quarter 2026 Financial Results

Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare ConferenceApril 24, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, April 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.







The BofA Securities 2026 Health Care Conference will be held on May 12-14, 2026, in Las Vegas, Nevada. Caris will present on Tuesday, May 12, from 10:00 - 10:30 AM PT.The Goldman Sachs 47th Annual Global Healthcare Conference will be held on June 8-10, 2026, in Miami, Florida. Caris will present on Monday, June 8, from 10:40 - 11:15 AM ET.  Live and replay webcasts will be available on the Investor Relations section of Caris' website at https://investor.carislifesciences.com.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 Investor Relations:
IR@CarisLS.com
917.689.3511



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-at-the-bofa-securities-2026-health-care-conference-and-the-goldman-sachs-47th-annual-global-healthcare-conference-302752499.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026April 20, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026.







Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About Caris Life Sciences 
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606Investor Relations:
IR@CarisLS.com
917.689.3511 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-first-quarter-2026-financial-results-on-may-7-2026-302746471.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer CenterApril 17, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research.







"Welcoming UCSF Helen Diller Family Comprehensive Cancer Center to the Caris Precision Oncology Alliance underscores the strength of our growing network," said James Hamrick, MD, MPH, Chairman of the Caris POA. "Their leadership in scientific discovery and patient-centered cancer care strengthens the collective expertise of our alliance and accelerates our shared mission to advance precision oncology. This participation will deepen collaborative research and expand access to cutting-edge molecular insights."Caris POA members advance precision medicine through collaborative research aimed at improving clinical outcomes for cancer patients. By harnessing Caris' advanced AI-driven machine learning platform and a vast multimodal database, the Caris POA accelerates discovery and translates innovative findings into more effective, personalized patient care."Precision medicine is advancing cancer care," said Emily Bergsland, MD, Director of the Center for Neuroendocrine Tumors at UCSF.  "We look forward to collaborating with Caris POA members to increase our understanding of the molecular underpinnings of cancer in order to improve risk stratification, individualize therapy, and optimize clinical outcomes."The UCSF Helen Diller Family Comprehensive Cancer Center, an NCI-designated cancer center, is recognized as one of the nation's premier institutions for cancer research, prevention and patient care. As part of UC San Francisco, the center brings together leading scientists, clinicians and specialists who work collaboratively to accelerate breakthroughs in cancer detection, treatment and survivorship. Its integrated approach connects cutting-edge laboratory discoveries with advanced clinical trials and compassionate, personalized care for patients across Northern California and beyond. With a strong commitment to equity, innovation and scientific excellence, the center continues to shape the future of oncology and expand the possibilities for patients and families facing cancer.The Caris POA comprises cancer centers, academic institutions, research consortia and healthcare systems, including NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Using Caris molecular profiling, which includes comprehensive genomic, transcriptomic and proteomic data, Caris aims to empower its network to prioritize therapeutic options and identify beneficial clinical trial opportunities for patients. Caris POA members can also participate in an expanding range of biomarker-directed trials sponsored by biopharmaceutical companies. Furthermore, Caris POA institutions have access to one of the industry's largest and most detailed multimodal databases, containing matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, with tens of billions of data points per patient.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? About UCSF
The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.?UCSF Health, which?serves as UCSF's primary academic medical center, includes?top-ranked specialty hospitals and?other clinical programs,?and has affiliations throughout the Bay Area.?UCSF School of Medicine also has a regional campus in Fresno. Learn more at?https://ucsf.edu or see our?Fact Sheet. Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-precision-oncology-alliance-welcomes-ucsf-helen-diller-family-comprehensive-cancer-center-302745224.htmlSOURCE Caris Life Sciences

Original: Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer PatientsApril 15, 2026 8:30 AM
PR Newswire (US)

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwideIRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.







Research published in JCO Oncology Practice found that 70% of U.S. counties had no active cancer treatment trials, leaving nearly one in five Americans ages 55 and older without a local pathway to investigational therapies. Nearly 85% of U.S. cancer patients receive care at community-based practices, yet most clinical trials remain concentrated at large academic medical centers. A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting the core barrier is access and infrastructure, not patient willingness.The Caris RIT clinical trial solution addresses this challenge by deploying trials directly to community oncology sites. Drawing on decades of oncology clinical trial experience, the system is designed to move from molecular profiling to patient enrollment in approximately two weeks and in as few as five days. Patients remain under the care of their treating oncologist, preserving continuity of care and eliminating the burden of long-distance travel to academic centers.The network of community and regional oncology sites now spans more than 600 locations, 2,200 investigators across the United States and Puerto Rico, with more than 71,000 patients identified for potential trial participation."Comprehensive molecular profiling gives oncologists a complete picture of each patient's disease, which is essential for identifying the most effective treatment options," said David Spetzler, MS, MBA, PhD, President of Caris Life Sciences. "When that profiling is paired with a system that matches patients to relevant clinical trials, we can significantly expand the range of therapeutic possibilities available to every patient."The gap between available science and clinical adoption illustrates why matching molecular profiles to clinical trials at the point of care has become an urgent priority in oncology. A Caris-led study of more than 295,000 real-world cancer patients, published in Nature Communications, examined the FDA's eight tissue-agnostic cancer approvals and found that for one of the most promising targets, NTRK fusion genes, roughly a third to nearly half of eligible patients with advanced disease never receive the approved therapy. The RIT clinical trial solution is designed to address this challenge of oncologists' limited familiarity with rare mutations and prescribing targeted therapies they encounter so infrequently.The RIT solution integrates comprehensive molecular profiling, automated trial matching, and streamlined site activation into a single workflow. Every patient whose tumor specimen is sent to Caris receives profiling through Whole Exome Sequencing (WES) of DNA, Whole Transcriptome Sequencing (WTS) of RNA and immunohistochemistry (IHC) analysis of proteins, covering more than 23,000 genes.A proprietary trial-matching platform then cross-references each patient's molecular results against the historical composition of the trial portfolio, comprising more than 30 clinical trials and more than 80 biopharmaceutical partners. Clinical Trial Navigators (CTNs), who are registered oncology nurses, notify treating physicians within 24 to 48 hours of identifying a match. CTNs conduct preliminary eligibility assessments and continue to monitor patients until the trial becomes a viable treatment option. Caris manages contracting, budgeting, site qualification and institutional review board (IRB) documentation, freeing physicians to focus on patient care.The RIT program draws on one of the largest clinico-genomic databases in oncology. As of December 31, 2025, Caris surpassed 1,016,000 total molecular tumor profiles and 740,000 matched profiles linking molecular data with clinical outcomes. The company has published findings from this research base in more than 1,050 peer-reviewed publications, often in collaboration with members of the Caris Precision Oncology Alliance, which includes cancer centers, academic and research centers."Every patient diagnosed with cancer deserves a treatment plan informed by the molecular profile of their disease," Spetzler said. "We believe the field is approaching a point where comprehensive profiling will become standard practice for all patients and programs like Right-In-Time are designed to accelerate that transition by connecting molecular insights directly to clinical trial opportunities at the community level."By embedding trial matching into the molecular profiling workflow and deploying trials at community sites, the RIT clinical trial solution aims to ensure that patients' ZIP codes do not determine whether they can access a potentially life-changing investigational therapy.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements 
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-right-in-time-clinical-trial-solution-expands-access-to-precision-oncology-trials-for-historically-underserved-cancer-patients-302742657.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid MalignanciesApril 2, 2026 8:30 AM
PR Newswire (US)

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insightIRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded.







Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician's overall clinical and pathological evaluation. Building on this foundation, the test delivers approximately 250x read depth across the genome with 40 million transcriptome reads, enabling enhanced genomic resolution from a bone marrow aspirate or peripheral blood collection. Results are synthesized into a single, easy-to-interpret, actionable report to support confident, timely clinical decision-making, with an expected seven-day turnaround time."The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real-world clinical workflows and provides results fast enough to inform patient care."The launch of Caris ChromoSeq underscores Caris Life Sciences' ongoing focus on advancing precision medicine through innovative molecular profiling technologies that simplify complexity and support clinicians across the cancer care continuum. About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris DetectMarch 31, 2026 6:00 PM
PR Newswire (US)

Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris' goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test. 







Caris Detect leverages Caris' industry-leading molecular profiling data, which has processed more than 1 million cases and generated more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify, with unprecedented resolution, difficult-to-detect biological signals associated with early-stage cancers. The Achieve 1 Study systematically assessed Caris Detect's diagnostic accuracy across a heterogeneous patient cohort, quantifying its efficacy in identifying multiple cancer types at early stages through peripheral blood sampling. A total of 3,014 subjects were enrolled and evaluable based on high-risk screening, symptomatic presentation, or identification of a mass on imaging, representing a population with elevated cancer prevalence relative to baseline.Achieve 1 results in totality included:
InterimBlindedTotalStage I Sensitivity56.8% (n=266)58.4% (n=77)56.8% (n=343)Stage II Sensitivity70.1% (n=137)63.0% (n=54)67.7% (n=191)Stage III Sensitivity77.1% (n=105)84.2% (n=38)79.0% (n=143)Stage IV Sensitivity99.1% (n=109)97.1% (n=36)98.6% (n=145)Asymptomatic
Specificity99.1% (n=121)100% (n=20)99.2% (n=141)Benign/High Risk
Specificity95.3% (n=1505)98.1% (n=546)96.0% (n=2051)Sensitivity in Stage I and II Cancers 60.3% (n=131)
Stage I & II SensitivityCancerInterimBlindedTotalBreast53.0% (n=253)  59.1% (n=44)53.7% (n=297)Prostate78.9% (n=38)  65.0% (n=20)74.1% (n=58)Lung86.7% (n=15)  60.0% (n=15)73.4% (n=30)Uterus73.7% (n=19)  46.1% (n=13)60.6% (n=32)Bowel62.2% (n=45)  60.0% (n=10)61.8% (n=55)Head and Neck100.0% (n=7)  66.7% (n=9)81.3% (n=16)Skin50.0% (n=2)  75.0% (n=4)66.7% (n=6)Pancreas71.4% (n=7)  66.7% (n=3)70.0% (n=10)Other88.2% (n=17)57.1% (n=13)69.7% (n=30)Of note, in the blinded validation set, 36 cancer patients had no staging information, 34 were on treatment or blood was collected after intent-to-treat surgery, and 24 failed to produce results meeting minimum sample quality metrics. Each of these patient groups were excluded from the results."Finalizing the Achieve 1 results is a pivotal milestone for Caris Detect, because it moves our performance assessment from an interim view to a complete, reported-out data set," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "This data was generated analyzing only one of nine pillars. With this study, we have validated that our Whole Genome Sequencing approach detects the diverse molecular changes that drive cancer and quantifies performance with greater confidence across stages and patient populations. This data reinforces our view that relying on a narrow slice of biology is not sufficient for early detection. We intend to add additional pillars, including Whole Transcriptome Sequencing, which we believe will strengthen and improve the overall performance of the test."About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.?Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.?Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com 
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-302730659.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung CancerMarch 26, 2026 8:30 AM
PR Newswire (US)

Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panelsIRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumor Board Report. These signatures assess the risk of patients developing brain metastases in breast and lung cancer. The addition of these two signatures brings the total number of proprietary Caris AI insights to seven, providing deeper insights to physicians and patients. This report, available upon request when ordering MI Cancer Seek® at no additional cost, provides clinicians with additional insights across all tumor types with specific algorithms for treatment decisions for colon, breast, ovarian, pancreatic and lung cancer.







Caris Life Sciences is accelerating the future of precision oncology by utilizing the world's most complete multimodal real-world dataset through its proprietary CodeAI™ platform, now exceeding over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS), H&E and IHC images with longitudinal follow-up clinical data. The novel Caris signatures for breast cancer and non-small cell lung cancer (NSCLC) predict a patient's risk of brain metastases. Brain metastases are a common and serious complication for a subset of breast and lung cancer patients, so identifying the risk for this type of complication early is a meaningful step to support more informed clinical decision-making."Insights from these proprietary Caris AI signatures give us a forward-looking view of which patients may be at elevated risk for brain metastases, allowing us to help guide clinicians to shift from passive surveillance to more proactive monitoring," said Caris President David Spetzler, MS, PhD, MBA. "Advanced clinical AI tools like Caris AI Insights are helping future-proof cancer care by integrating molecular intelligence into everyday decision making, so that we can personalize care earlier and with greater precision."The brain metastases signatures were trained on a large set of 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes. The signatures generate a personalized predictive score using each patient's WES and WTS data. Results are visualized as Kaplan-Meier curves, providing clinicians with an intuitive view of the likelihood and rate of brain metastasis development based on the patient's molecular profile.Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.A study is in progress with collaborators of the Caris Precision Oncology Alliance® (POA®) to highlight how risk prediction for brain metastases in breast and lung cancer patients is achieved using Caris AI Insights. The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research. About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer-302725638.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026March 25, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026.







These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing precision oncology through deep molecular interrogation. The studies focused on breast, prostate, lung and colorectal cancers represent a collaborative effort between Caris and leading cancer centers and institutions, underscoring the power of large-scale, real world molecular evidence to accelerate discovery and improve patient outcomes."These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden," said James Hamrick, MD, MPH, Chairman of the Caris POA. "By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients."Posters Include:Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer
Session: Spatial Proteomics and Transcriptomics 1
Sunday, April 19, 2026, 2:00 PM – 5:00 PM PST
Poster #: 1200/1
Location: Poster section 47Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC
Session: Biomarkers Predictive of Therapeutic Benefit 3
Monday, April 20, 2026, 9:00 AM – 12:00 PM PST
Poster #: 2434/4
Location: Poster section 40AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)
Session: Molecular Targeted Therapy
Monday, April 20, 2026, 2:00 PM – 5:00 PM PST
Poster #: 3910/16
Location: Poster section 47cBioPortal for cancer genomics
Session: AACR Project GENIE: Genomic Characterization
Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PST
Poster #: 4097/2
Location: Poster section 1Distinct KRAS mutation codons differentially associate with microsatellite instability in colorectal carcinoma
Session: Precision Oncology and Real World Data
Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PST
Poster #: 5336/4
Location: Poster section 46MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance
Session: Real World Data to Provide Real World Evidence
Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PST
Poster #: 6647/16
Location: Poster section 47Research highlights will be available onsite at Caris' booth #1423. The full abstracts will be available on the Caris website following the presentations.About Caris Life Sciences 
Caris Life Sciences® (Caris) is a?leading,?patient-centric, next-generation AI?TechBio?company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal?clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy?selection?and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve?the human?condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:
Corporate Communications?
CorpComm@CarisLS.com?
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-six-oncology-studies-utilizing-proprietary-multimodal-data-at-the-aacr-annual-meeting-2026-302724354.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer PatientsMarch 20, 2026 8:30 AM
PR Newswire (US)

Highlighting the critical role of Caris GPSai in improving cancer careIRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types. 







This paper demonstrates that by including AI algorithms as part of routine comprehensive molecular profiling, clinicians can uncover clinically significant misdiagnoses in cases labeled as lung squamous cell carcinoma (SCC), influencing treatment decisions and patient outcomes. The study comprised 3,958 lung cancer cases submitted to Caris with a diagnosis of SCC. Caris GPSai® identified 123 of the 3,958 cases were metastases from other primary sites, including cutaneous, urothelial, head and neck and thymic cancers.The clinical impact of reclassification underscores the power of precision medicine. The study identified 88 patients (71.5%) who had guideline-preferred first-line systemic therapy change recommendations, alerting clinicians that a change in their patients' treatments would achieve better outcomes. According to the CDC website, lung SCC accounts for roughly 21% of all lung cancer cases in the United States. Applying study-specific stats to the wider CDC data for lung cancer in the United States suggests that approximately 1,000 cases each year may be potential misdiagnoses."Caris GPSai has overturned 3,857 diagnoses across the spectrum of cancer since January of 2024," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "By integrating AI-driven tissue-of-origin predictions with comprehensive molecular profiling and pathology, we can give clinicians greater diagnostic confidence and ensure patients receive the most appropriate care."These misdiagnoses carry direct and life-altering clinical consequences, as treatment recommendations and prognostic expectations differ significantly across cancer types. By embedding Caris GPSai into Caris' comprehensive molecular profiling, providers gain an additional layer of insight that can help patients get the healthcare they deserve.The GPSai algorithm is included as part of MI Cancer Seek® and MI Tumor Seek® at no additional cost. Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-another-breakthrough-study-for-gpsai-in-identifying-and-correcting-misdiagnosis-of-cancer-patients-302719396.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian CancerMarch 16, 2026 8:30 AM
PR Newswire (US)

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.







Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.By harnessing AI across its comprehensive real-world database, Caris is building next-generation multimodal models that accelerate biomarker discovery, enhance therapeutic decision-making and support the development of more personalized cancer treatments.HGSOC is the most common and aggressive type of ovarian cancer and is often diagnosed at an advanced stage, creating urgency in treatment planning. Platinum resistance, defined as disease progression or recurrence within six months of finishing first-line platinum-based chemotherapy, is estimated to affect 20-30% of patients with advanced HGSOC. For clinicians, understanding a patient's likelihood of chemotherapy resistance can guide the creation of a patient-specific treatment plan.The ovarian platinum resistance signature is particularly relevant in light of the recent FDA approval of a combination therapy for patients with platinum-resistant disease. The FDA approved a new combination treatment that opens the door to another option for patients whose cancer has stopped responding to initial platinum-based chemotherapy. The approval underscores the importance of identifying resistance earlier in the treatment course so clinicians can make more informed decisions about subsequent therapy."The ability to anticipate which patients are likely to develop early platinum resistance has the potential to significantly improve how we approach ovarian cancer care," said David Spetzler, MS, PhD, MBA, Caris President. "Platinum-based chemotherapy works well for many patients, but when it doesn't, patients need to be able to quickly move on to other therapeutic options."  By identifying complex molecular features associated with platinum resistance, this signature generates a risk score and a "platinum sensitive" or "platinum resistant" prediction that estimates the likelihood of early transition to the next line of treatment using features from the Caris industry-leading Whole Exome and Whole Transcriptome tissue platform. Also, clinicians receive supporting Kaplan-Meier curves to help contextualize the risk and assist with treatment planning. The Caris AI Insights for ovarian cancer is available now, by request, through the Caris Molecular Tumor Board Report when ordering Caris' tissue-based test, MI Cancer Seek®.Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.  About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-introduces-powerful-new-caris-ai-insights-to-identify-early-platinum-resistance-in-ovarian-cancer-302714113.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual MeetingMarch 11, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026.







Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented. The studies, including one oral presentation and four posters, will cover soft tissue and bone sarcomas, melanoma and gastrointestinal stromal tumors. These posters and presentation represent a collaborative effort between Caris and over 20 cancer centers and institutions across the United States and Europe."USCAP offers a great opportunity for pathologists to showcase the latest advances and publications in our industry. We're presenting across multiple topics, incorporating real-world outcomes and uncovering insights that bring us closer to truly personalized treatment pathways," said Matthew Oberley, MD, PhD, SVP, Chief Clinical Officer and Pathologist-in-Chief at Caris.  ? Oral Presentation:BCORL1::CREBBP Fusions Characterize an Aggressive Frequently Ossifying Bone and Soft Tissue Sarcoma with Predilection for the Clavicular Bone. Oral #808Platform - Tuesday PM - Bone and Soft Tissue Pathology. March 24, 2026. Presentation Time:  2:00 PM – 2:15 PM CDTPosters Include:Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study. Poster #48Poster II - Monday PM - Dermatopathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDTComprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and Genomic Correlates. Poster #69Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDTSecondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma: Beyond NR4A3. Poster #70Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDTInterplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correlation with Clinicopathologic Features, Comprehensive Genomic Profile, and Disease Outcome. Poster #63Poster IV – Tuesday PM – Bone and Soft Tissue Pathology. March 24, 2026. Time:  1:00 PM – 4:30 PM CDTResearch highlights will be available onsite at Caris' booth #512. The full abstracts will be available on the Caris website following the presentations.About Caris Life Sciences 
Caris Life Sciences® (Caris) is a?leading,?patient-centric, next-generation AI?TechBio?company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal?clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy?selection?and drug development.?? Caris was founded with a vision to realize the potential of precision medicine to improve?the human?condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.?? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Caris Life Sciences Media:
Corporate Communications?
CorpComm@CarisLS.com?
214.294.5606? 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-showcase-five-studies-at-the-2026-uscap-annual-meeting-302710422.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic CancerMarch 9, 2026 8:30 AM
PR Newswire (US)

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report.  The Caris Molecular Tumor Board Report is an innovative tumor profiling report that provides an additional tumor biology resource and is available upon request with no additional tissue sampling required when ordering MI Cancer Seek®.







Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets, available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.By harnessing AI across its comprehensive real-world datasets, comprised of over 550,000 patients, Caris researchers are building next-generation multimodal models that accelerate biomarker discovery, enhance therapeutic decision-making, and support the development of more personalized cancer treatments.This signature, designed to support first-line treatment selection for patients with pancreatic ductal adenocarcinoma (PDAC), leverages Caris' WES and WTS to provide biologically informed insights that may help clinicians personalize therapy decisions in one of the deadliest and most treatment-challenging cancers. FOLFIRINOX and gemcitabine/nab-paclitaxel (gem/nab-p) are the most commonly used first-line regimens for advanced PDAC, yet limited actionable biomarker guidance exists for therapy selection. As a result, treatment selection often relies on clinical factors rather than tumor biology, exposing patients to potentially unnecessary toxicity with limited benefit."Caris AI Insights for PDAC represents a meaningful step forward in bringing molecular intelligence to a disease where clinicians have historically had to make difficult treatment decisions with limited biological guidance," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "By harnessing the power of WES and WTS, this Caris AI Insights signature identifies complex molecular patterns that may predict differential benefit between standard first-line regimens. This is exactly the type of advancement to improve patient care that our comprehensive platform was built to deliver."The PDAC signature provides clinicians with risk categorization (standard or high risk) and treatment recommendations between FOLFIRINOX and gem/nab-p, based on molecular patterns associated with differential benefit. The report includes a Kaplan-Meier plot for patients treated with either regimen, matching the predictions to the clinicians' patients to advise likely responses.Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors. A future publication is expected this year, highlighting how Caris AI Insights for pancreatic cancer identified a significant subset of patients who may be candidates for treatment de-escalation, as well as those more likely to benefit from a more intensive regimen and those who likely need the more intensive therapy.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.? Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.? Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.   You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com 
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-launches-a-novel-caris-ai-insights-signature-to-guide-first-line-therapy-selection-and-treatment-de-escalation-in-pancreatic-cancer-302707404.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer

/C O R R E C T I O N -- Caris Life Sciences/February 26, 2026 6:59 PM
PR Newswire (US)

In the news release, Caris Life Sciences Completes Interim Readout of Achieve 1 Study, issued 26-Feb-2026 by Caris Life Sciences over PR Newswire, we are advised by the company that PR Newswire incorrectly placed the second line of the headline as a sub-headline. The complete, corrected release follows, with additional details at the end:
Caris Life Sciences Completes Interim Readout of Achieve 1 Study Demonstrates Superior Sensitivity and Specificity of Caris Detect
Results demonstrate the superiority of Whole Genome Sequencing compared 
to methylation-based approaches
IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.







Caris Detect leverages Caris' industry-leading molecular profiling data, which has surpassed one million cases processed and produced more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify subtle biological signals associated with early-stage cancers with unprecedented resolution. Achieve 1 is evaluating Caris Detect across a broad population of patients, assessing its ability to detect multiple cancer types at early stages using a blood draw. For the undiagnosed cohort, which consisted of 1,505 samples, we utilized blood draws from subjects who had screening or symptomatic screening, a population reflecting a higher likelihood of cancer than the general population. We followed 22.5% of the subjects for approximately one year following their blood draw. Of these, 121 subjects had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer, representing a healthy population.The first phase of Achieve 1 utilized a cross-validation approach, with approximately 865 samples held out for a blinded validation that is in process. Caris expects to report those results later in the first quarter of 2026.Study highlights and key performance data from the interim readout include:Sensitivity:56.8% for Stage I (n=266)70.1% for Stage II (n=137)77.1% for Stage III (n=105)99.1% for Stage IV (n=109)Sensitivity in Stage I and II Cancers (61.3% sensitivity)






CancerStage I-II






Breast53.0% (n=253)






Bowel62.2% (n=45)






Prostate78.9% (n=38)






Uterus73.7% (n=19)






Lung86.7% (n=15)






Pancreas71.4% (n=7)






Head and Neck100.0% (n=7)






Esophagus/Stomach80.0% (n=5)






Cervix80.0% (n=5)






Biliary Tract100% (n=3)






Skin50.0% (n=2)






Liver100% (n=2)






Peritoneum100% (n=1)






Bone100% (n=1)Specificity: 99.1% in the Asymptomatic Screening Population (n=121) and 95.3% in the Undiagnosed Population (n=1,505).Sample Size: 2,122, across 1,505 undiagnosed and 617 cancers from stages I through IV.1,505 undiagnosed subjects from a screening and symptomatic screening population (the "Undiagnosed Population").121 of these subjects with follow-up data had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer within one year following blood draw (the "Asymptomatic Screening Population").In the ~600 undiagnosed subjects with one year of follow-up, roughly 7% of patients were subsequently diagnosed with cancer, indicating our enrollment criteria enriched for high-risk subjects."Our hypothesis has been that cancer is a disease driven by molecular aberrations that can manifest itself in many different forms. For example, driver mutations, changes in epigenomics, changes in transcriptomics and changes in aneuploidy," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "Most other attempts to derive insights into blood-based early detection modalities have relied upon epigenomics. Caris approached this from a broader biological perspective to encompass as many genomic alterations as can be attained from extreme ultra-deep Whole Genome Sequencing. This additional data has allowed us to achieve greater performance metrics than others and shows that methodologies focused on limited biological information are not sufficient to encompass the diversity of molecular aberrations driving cancer, especially in early-stage disease. Development of the next version of Caris Detect is currently underway with the aim of improving the already best-in-class performance with the incorporation of Whole Transcriptome Sequencing."About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: technical, operational and implementation requirements the failure of which affect the timing of or prevent commercialization of Caris Detect; future results regarding the blinded hold-out portion of the Achieve 1 samples as well as samples from Achieve 2; future performance and clinical utility of Caris Detect, including its AI models, when applied across larger real-world screening populations; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on or about March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606Correction: An earlier version of this release incorrectly placed the second half of the headline as a sub-headline.  



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-completes-interim-readout-of-achieve-1-study-302699083.htmlSOURCE Caris Life Sciences

Original: /C O R R E C T I O N -- Caris Life Sciences/

Caris Life Sciences Completes Interim Readout of Achieve 1 StudyFebruary 26, 2026 6:00 PM
PR Newswire (US)

Demonstrates Superior Sensitivity and Specificity of Caris DetectResults demonstrate the superiority of Whole Genome Sequencing compared 
to methylation-based approaches
IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.







Caris Detect leverages Caris' industry-leading molecular profiling data, which has surpassed one million cases processed and produced more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify subtle biological signals associated with early-stage cancers with unprecedented resolution. Achieve 1 is evaluating Caris Detect across a broad population of patients, assessing its ability to detect multiple cancer types at early stages using a blood draw. For the undiagnosed cohort, which consisted of 1,505 samples, we utilized blood draws from subjects who had screening or symptomatic screening, a population reflecting a higher likelihood of cancer than the general population. We followed 22.5% of the subjects for approximately one year following their blood draw. Of these, 121 subjects had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer, representing a healthy population.The first phase of Achieve 1 utilized a cross-validation approach, with approximately 865 samples held out for a blinded validation that is in process. Caris expects to report those results later in the first quarter of 2026.Study highlights and key performance data from the interim readout include:Sensitivity:56.8% for Stage I (n=266)70.1% for Stage II (n=137)77.1% for Stage III (n=105)99.1% for Stage IV (n=109)Sensitivity in Stage I and II Cancers (61.3% sensitivity)






CancerStage I-II






Breast53.0% (n=253)






Bowel62.2% (n=45)






Prostate78.9% (n=38)






Uterus73.7% (n=19)






Lung86.7% (n=15)






Pancreas71.4% (n=7)






Head and Neck100.0% (n=7)






Esophagus/Stomach80.0% (n=5)






Cervix80.0% (n=5)






Biliary Tract100% (n=3)






Skin50.0% (n=2)






Liver100% (n=2)






Peritoneum100% (n=1)






Bone100% (n=1)Specificity: 99.1% in the Asymptomatic Screening Population (n=121) and 95.3% in the Undiagnosed Population (n=1,505).Sample Size: 2,122, across 1,505 undiagnosed and 617 cancers from stages I through IV.1,505 undiagnosed subjects from a screening and symptomatic screening population (the "Undiagnosed Population").121 of these subjects with follow-up data had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer within one year following blood draw (the "Asymptomatic Screening Population").In the ~600 undiagnosed subjects with one year of follow-up, roughly 7% of patients were subsequently diagnosed with cancer, indicating our enrollment criteria enriched for high-risk subjects."Our hypothesis has been that cancer is a disease driven by molecular aberrations that can manifest itself in many different forms. For example, driver mutations, changes in epigenomics, changes in transcriptomics and changes in aneuploidy," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "Most other attempts to derive insights into blood-based early detection modalities have relied upon epigenomics. Caris approached this from a broader biological perspective to encompass as many genomic alterations as can be attained from extreme ultra-deep Whole Genome Sequencing. This additional data has allowed us to achieve greater performance metrics than others and shows that methodologies focused on limited biological information are not sufficient to encompass the diversity of molecular aberrations driving cancer, especially in early-stage disease. Development of the next version of Caris Detect is currently underway with the aim of improving the already best-in-class performance with the incorporation of Whole Transcriptome Sequencing."About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: technical, operational and implementation requirements the failure of which affect the timing of or prevent commercialization of Caris Detect; future results regarding the blinded hold-out portion of the Achieve 1 samples as well as samples from Achieve 2; future performance and clinical utility of Caris Detect, including its AI models, when applied across larger real-world screening populations; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on or about March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-completes-interim-readout-of-achieve-1-study-302699083.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Completes Interim Readout of Achieve 1 Study

Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 OutlookFebruary 26, 2026 4:05 PM
PR Newswire (US)

Full year revenue growth of 97% driven by strong performance in molecular profiling servicesExpects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billionIRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025.







Fourth Quarter 2025 Financial HighlightsReported total revenue of $292.9 million, an increase of 125% over the corresponding prior year period.Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% over the corresponding prior year period, and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.Reported gross margin of 75%, an approximate 2,000 bps improvement over the corresponding prior year period.Reported net income of $82.0 million.Reported positive Adjusted EBITDA of $106.1 million.Reported positive net cash provided by operating activities of $44.8 million, and positive free cash flow of $39.7 million.Full Year 2025 Financial HighlightsReported total revenue of $812.0 million, an increase of 97% over the corresponding prior year.Completed approximately 199,300 clinical therapy selection cases, an increase of approximately 22% over the corresponding prior year, and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.Reported gross margin of 66%, an approximate 2,300 bps improvement over the corresponding prior year period.Reported net loss of $68.1 million.Reported positive Adjusted EBITDA of $137.7 million.Reported positive net cash provided by operating activities of $83.2 million, and positive free cash flow of $66.9 million."Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris and an important step forward for precision medicine," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.Recent Operating HighlightsSurpassed 1,016,000 total profiles and 740,000 total matched profiles through December 31, 2025.More than 627,000 Whole Exome and 678,000 Whole Transcriptome profiles through December 31, 2025.Announced partnership with Everlywell to launch Caris' forthcoming MCED assay, Caris Detect.Announced collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need.Fourth Quarter 2025 Financial ResultsTotal revenue was $292.9 million for the three months ended December 31, 2025, compared to $129.9 million for the three months ended December 31, 2024, an increase of $163.0 million, or 125%.The increase in total revenue was driven primarily by a 199% growth in molecular profiling services revenue, which was $282.1 million for the three months ended December 31, 2025, compared to $94.4 million for the three months ended December 31, 2024. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions.Gross profit, calculated as total revenue less cost of services, for the three months ended December 31, 2025 and 2024, was $220.9 million and $70.7 million, respectively, representing a gross margin of 75% and 54%, respectively.Operating expenses were $132.5 million for the three months ended December 31, 2025, compared to $107.7 million for the three months ended December 31, 2024, an increase of $24.8 million, or 23%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.Net income was $82.0 million for the three months ended December 31, 2025, as compared to a net loss of $36.9 million for the three months ended December 31, 2024. Net income per share attributable to common shareholders, basic and diluted, was $0.29 and $0.28 per share, respectively, for the three months ended December 31, 2025, as compared to a net loss per share attributable to common shareholders, basic and diluted, of $1.73, for the three months ended December 31, 2024.Net cash provided by operating activities was $44.8 million for the three months ended December 31, 2025, as compared to net cash used in operating activities of $38.9 million for the three months ended December 31, 2024, a 215% improvement. The improvement was driven by improved reimbursement from molecular profiling services.Full Year 2025 Financial ResultsTotal revenue was $812.0 million for the year ended December 31, 2025, compared to $412.3 million for the year ended December 31, 2024, an increase of $399.8 million, or 97%.The increase in total revenue was driven primarily by a 120% growth in molecular profiling services revenue, which was $766.7 million for the year ended December 31, 2025, compared to $349.1 million for the year ended December 31, 2024. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions.Gross profit, calculated as total revenue less cost of services, for the years ended December 31, 2025 and 2024 was $539.2 million and $178.8 million, respectively, representing a gross margin of 66% and 43%, respectively.Operating expenses were $494.1 million for the year ended December 31, 2025, compared to $435.9 million for the year ended December 31, 2024, an increase of $58.2 million, or 13%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.Net loss was $68.1 million for the year ended December 31, 2025, as compared to a net loss of $281.9 million for the year ended December 31, 2024. Net loss per share attributable to common shareholders, basic and diluted, was $3.22 per share for the year ended December 31, 2025, as compared to a net loss per share attributable to common shareholders, basic and diluted, of $10.66 for the year ended December 31, 2024.Net cash provided by operating activities was $83.2 million for the year ended December 31, 2025, as compared to net cash used in operating activities of $245.2 million for the year ended December 31, 2024, a 134% improvement. The improvement was driven by improved reimbursement from molecular profiling services.2026 Financial Outlook and GuidanceCaris Life Sciences expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to full year 2025. Clinical therapy selection volume is expected to grow approximately 20% compared to full year 2025.Within this revenue range:Molecular profiling revenue is expected to grow approximately 21% to 22% year over year in 2026. Excluding out-of-year revenue from over collections recorded in 2025, this range implies growth of approximately 26% to 28%.Pharma & research revenue is expected to be in the range of $75 million to $85 million for the year ending December 31, 2026.Caris Life Sciences expects GAAP operating expenses to be in the range of $590 million to $595 million, representing a 19% to 20% increase due to commercial expansion and increase in pipeline trial activities, and expects to remain positive on Free Cash Flow and Adjusted EBITDA.Conference Call InformationEvent:
Caris Fourth Quarter 2025 Financial Results Conference CallDate:
Thursday, February 26, 2026Time:
3:30 p.m. CT (4:30 p.m. ET)Webcast Link:
https://edge.media-server.com/mmc/p/49czfgs4Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call. A replay of the conference call will be available on our investor relations website shortly after the conclusion of the call.About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.We intend to use the investor page of our website, https://investor.carislifesciences.com, as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases, SEC filings, public conference calls and webcasts.Forward-Looking StatementsThis press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on or about March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.Non-GAAP MeasuresWe use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States ("GAAP"), to supplement our consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges.We define free cash flow as net cash provided by (used in) operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash.A reconciliation of the historical non-GAAP financial measures used in this press release to the respective comparable GAAP financial measures, can be found below.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606Investor Relations:
InvestorRelations@CarisLS.com
917.689.3511 Caris Life Sciences, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(unaudited) 
(amounts in thousands, except share and per share data)Three Months Ended
December 31,
Years Ended December 31,
2025
2024
2025
2024







Revenue:






Molecular profiling services$         282,126
$           94,423
$         766,719
$         349,115Pharma research and development services10,760
35,492
45,314
63,145Total revenue292,886
129,915
812,033
412,260Costs and operating expenses:






Cost of Services - Molecular profiling services69,158
55,941
262,353
223,075Cost of Services - Pharma research and development services2,814
3,273
10,512
10,403Selling and marketing expense44,151
37,525
167,506
152,602General and administrative expense56,507
43,113
224,965
169,386Research and development expense31,845
27,109
101,584
113,916Total costs and operating expenses204,475
166,961
766,920
669,382Income (Loss) from operations88,411
(37,046)
45,113
(257,122)Other expense, net:






Interest income7,015
970
16,497
7,122Interest expense(11,356)
(13,262)
(56,853)
(50,025)Changes in fair value of financial instruments—
12,417
(52,285)
18,484Other expense, net(2,113)
(26)
(20,560)
(349)Total other expense, net(6,454)
99
(113,201)
(24,768)Income (Loss) before income taxes and provision for income taxes81,957
(36,947)
(68,088)
(281,890)Provision for income taxes—
—
—
—Net income (loss)81,957
(36,947)
(68,088)
(281,890)Other comprehensive income, net of tax:






Unrealized gain on available-for-sale securities—
—
—
7Foreign currency translation adjustments188
5
726
(15)Comprehensive income (loss)82,145
(36,942)
(67,362)
(281,898)







Net income (loss) attributable to common shareholders:






Net income (loss)81,957
(36,947)
(68,088)
(281,890)Deemed dividend from Series D redeemable convertible preferred stock—
—
(384,436)
—Adjustments of redeemable convertible preferred stock to redemption value—
(24,999)
(85,433)
(96,367)Net income (loss) attributable to common shareholders$           81,957
$          (61,946)
$       (537,957)
$       (378,257)







Net income (loss) per share attributable to common shareholders:






Basic$                0.29
$              (1.73)
$              (3.22)
$            (10.66)Diluted$                0.28
$              (1.73)
$              (3.22)
$            (10.66)







Weighted-average shares used in computing net income (loss) per share
attributable to common shareholders:






Basic282,215,465
35,828,916
167,205,616
35,496,832Diluted296,089,041
35,828,916
167,205,616
35,496,832 Caris Life Sciences, Inc.Condensed Consolidated Balance Sheets(unaudited) 
(amounts in thousands, except share data)As of December 31,
2025
2024



Assets


Current assets:


Cash, cash equivalents, and restricted cash$         797,799
$           65,442Short-term marketable securities2,295
2,201Accounts receivable112,140
88,244Supplies63,625
39,572Prepaid expenses and other current assets21,941
20,270Total current assets997,800
215,729Property and equipment, net63,170
67,817Goodwill19,344
19,344Other assets45,349
40,844Total assets$      1,125,663
$         343,734Liabilities, Redeemable Convertible Preferred Stock, and Shareholders' Equity (Deficit)


Current liabilities:


Accounts payable$           39,206
$           27,791Accrued expenses and other current liabilities87,770
77,542Current portion of indebtedness169
60,090Total current liabilities127,145
165,423Long-term indebtedness, net of debt discounts378,823
319,438Warrant liabilities—
91,642Other long-term liabilities42,388
44,418Total liabilities548,356
620,921Commitments and contingencies


Redeemable convertible preferred stock:


Series A preferred stock, par value $0.001: no and 490,000,000 shares authorized as of
December 31, 2025 and December 31, 2024, respectively; no and 485,795,293 shares
issued and outstanding as of December 31, 2025 and December 31, 2024, respectively;
and $296,335 aggregate liquidation preference as of December 31, 2024—
709,261Series B preferred stock, par value $0.001: no and 30,000,000 shares authorized as of
December 31, 2025 and December 31, 2024, respectively; no and 29,629,630 shares
issued and outstanding as of December 31, 2025 and December 31, 2024, respectively;
and $16,000 aggregate liquidation preference as of December 31, 2024—
42,963Series C preferred stock, par value $0.001: no and 142,000,000 shares authorized as of
December 31, 2025 and December 31, 2024, respectively; no and 116,200,835 shares
issued and outstanding as of December 31, 2025 and December 31, 2024, respectively;
and $408,715 aggregate liquidation preference as of December 31, 2024—
408,715Series D preferred stock, par value $0.001: no and 102,600,000 shares authorized as of
December 31, 2025 and December 31, 2024, respectively; no and 102,516,283 shares
issued and outstanding as of December 31, 2025 and December 31, 2024, respectively;
and $1,060,712 aggregate liquidation preference as of December 31, 2024—
1,060,712Redeemable convertible preferred stock—
2,221,651Shareholders' equity (deficit):


Preferred stock, $0.001 par value per share; 100,000,000 and no shares authorized as of
December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding
as of December 31, 2025 and December 31, 2024—
—Common stock $0.001 par value; 2,800,000,000 and 1,150,000,000 shares authorized as of
December 31, 2025 and December 31, 2024, respectively; 284,137,810 and 36,686,819 shares
issued as of December 31, 2025 and December 31, 2024, respectively; 282,526,097 and
36,504,319 shares outstanding as of December 31, 2025 and December 31, 2024, respectively;
shares issued and outstanding include 23,446 and 662,000 unvested shares subject to repurchase
as of December 31, 2025 and December 31, 2024, respectively283
38Treasury stock at cost, 1,611,713 and 182,500 shares of common stock as of December 31, 2025
and December 31, 2024, respectively(16,896)
(330)Additional paid-in capital3,141,720
—Related party promissory note receivable—
(26,456)Accumulated deficit(2,548,736)
(2,472,300)Accumulated other comprehensive income936
210Total shareholders' equity (deficit)577,307
(2,498,838)Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit)$      1,125,663
$         343,734 Caris Life Sciences, Inc.Condensed Consolidated Statement of Cash Flows(unaudited) 
(amounts in thousands)Years Ended December 31,
2025
2024



Cash flows from operating activities


Net loss$          (68,088)
$       (281,890)Adjustments to reconcile net loss to net cash used in operating activities:


Depreciation and amortization22,615
48,913Stock-based compensation expense70,006
18,643Non-cash operating lease expense5,585
5,601Amortization of debt discounts12,768
7,054Changes in fair value of financial instruments52,285
(18,484)Loss on debt extinguishment19,895
—Other1,216
4,031Changes in operating assets and liabilities:


Accounts receivable(29,789)
(33,816)Supplies(20,750)
5,459Prepaid expenses and other current assets(5,150)
(1,408)Other assets48
121Accounts payable11,035
(226)Accrued expenses and other liabilities11,479
803Net cash provided by (used in) operating activities83,155
(245,199)



Cash flows from investing activities


Maturities of marketable securities—
61,376Purchases of property and equipment(16,260)
(8,444)Net cash provided by (used in) investing activities(16,260)
52,932



Cash flows from financing activities


Payments made on finance lease obligations(106)
(157)Proceeds from exercise of stock options7,637
1,530Payment of taxes withheld from net settlement of exercised options and vested (18,551)
—Payment of deferred offering costs(7,710)
(1,059)Proceeds from the 2023 term loan, net of issuance costs—
199,978Repurchase of common stock(113)
—Issuance of Series E Preferred Stock, net of issuance costs87,637
—Issuance of Series F Preferred Stock, net of issuance costs33,601
—Issuance of the 2025 Convertible Notes, net of issuance costs27,865
—Issuance of the 2025 Warrants10,270
—Payments of 2023 term loan amendment fee(4,000)
—Proceeds from initial public offering, net of underwriting discounts and commissions528,459
—Net cash provided by financing activities664,989
200,292



Effect of exchange rate changes on cash, cash equivalents, and restricted cash130
(4)Net increase in cash, cash equivalents, and restricted cash732,014
8,021



Cash, cash equivalents, and restricted cash at beginning of period68,028
60,007Cash, cash equivalents, and restricted cash at end of period$         800,042
$           68,028 Reconciliation of GAAP Net Loss to Adjusted EBITDA(unaudited) 
(amounts in thousands)Three Months Ended
December 31,
Years Ended December 31,
2025
2024
2025
2024







Net loss$           81,957
$          (36,947)
$          (68,088)
$       (281,890)Interest income(7,015)
(970)
(16,497)
(7,122)Interest expense11,356
13,262
56,853
50,025Changes in fair value of financial instruments—
(12,417)
52,285
(18,484)Other expense, net2,113
26
20,560
349Provision for income taxes—
—
—
—Depreciation and amortization expense4,291
9,066
22,615
48,913Stock-based compensation expense13,367
4,977
70,006
18,643Adjusted EBITDA$         106,069
$          (23,003)
$         137,734
$       (189,566) Reconciliation of Net Cash Provided by (Used in) Operating Activities to Free Cash Flow(unaudited) 
(amounts in thousands)Three Months Ended
December 31,
Twelve Months Ended
December 31,
2025
2024
2025
2024







Net cash provided by (used in) operating activities$           44,780
$          (38,922)
$           83,155
$       (245,199)Less: purchases of property and equipment(5,090)
(2,290)
(16,260)
(8,444)Free cash flow$           39,690
$          (41,212)
$           66,895
$       (253,643) 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook-302697700.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy DrugFebruary 24, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that provides an additional tumor biology resource and is available upon request when ordering MI Cancer Seek®.







The Caris AI Insights section of the Caris Molecular Tumor Board Report includes signatures powered by artificial intelligence, including proprietary Caris signatures. These signatures leverage Caris' clinico-genomic data in predicting therapy response, identifying tissue of origin, assessing metastasis risk and guiding personalized treatment strategies for each patient.Caris recently added the breast cancer signature for capecitabine to the Caris AI Insights section of the Caris Molecular Tumor Board Report. The signature utilizes more than 2,000 expression and copy number features from a patient's Whole Exome and Whole Transcriptome profile to predict response to capecitabine for first-line chemotherapy in HER2-negative breast cancer patients. Capecitabine is an oral chemotherapy drug used to treat breast cancer, among other cancers."Molecular profiling is a vital step in gaining a comprehensive understanding of a patient's cancer," said Caris President David Spetzler, MS, PhD, MBA. "Caris AI Insights help researchers and clinicians provide a valuable molecular blueprint of a patient's tumor biology and is another way Caris' testing goes above and beyond for patients, clinicians and researchers." The Caris Molecular Tumor Board Report is available upon request when ordering MI Cancer Seek.Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.?Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: 
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-launches-proprietary-ai-insights-signature-which-deepens-understanding-of-response-to-breast-cancer-patients-oral-chemotherapy-drug-302695325.htmlSOURCE Caris Life Sciences

Original: Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug

Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 23, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, Feb. 23, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts.







About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition.?Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 Investor Relations:
IR@CarisLS.com
917.689.3511



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302694075.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference

Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26February 9, 2026 8:30 AM
PR Newswire (US)

IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.







Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Conference Call Details:Date: Thursday, February 26, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606Investor Relations:
IR@CarisLS.com
917.689.3511



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-302681818.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab DeruxtecanJanuary 28, 2026 1:30 PM
PR Newswire (US)

IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. This study explains why patient responses vary and reveals how resistance can evolve over time.







This study addresses a critical gap in understanding why responses to T–DXd, an antibody–drug conjugate approved by the FDA for HER2-positive and HER2-low metastatic breast cancer, vary widely since resistance to T–DXd is common. By combining large-scale, real-world clinical outcomes with Caris's comprehensive molecular profiling, including whole exome sequencing (WES) and whole transcriptome sequencing (WTS), the study enables a population-level analysis of resistance pathways across DNA, RNA and protein expression."In this large real-world analysis, clinical outcomes allowed Caris to pinpoint molecular features linked to treatment-specific survival,"?said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer.?"Post–treatment molecular shifts further reveal biologically plausible routes to acquired resistance, underscoring that RNA–level and multiomic profiling can provide actionable insights beyond standard HER2 classification to better stratify patients and inform therapies." The study analyzed 2,799 T–DXd–treated breast cancer patients and found that WTS identified ERBB2 (HER2) and ABCC1 as the strongest transcriptomic predictors of T–DXd–specific overall survival. Higher ERBB2 expression correlated with improved outcomes, while higher ABCC1 correlated with poorer outcomes, independent of HER2 category.ABCC1 further stratified outcomes within HER2–defined subgroups, indicating predictive value beyond standard HER2 testing and post–treatment samples showed increased ABCC1 expression alongside enrichment of mutations in ERBB2, NFE2L2, KEAP1 and TOP1. Consistent with acquired resistance mechanisms. Preclinical models supported a functional, context–dependent role for ABCC1–mediated drug efflux in T–DXd resistance."This study demonstrates how population–scale, multiomic real–world data can drive high impact translational discoveries, reinforcing the value proposition for patients and equipping biopharma with actionable insights into resistance biology to guide next–generation drug development," said David Spetzler, MS, PhD, MBA, Caris President.About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606



View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-real-world-data-uncovers-metastatic-breast-cancer-patient-responses-and-resistance-to-trastuzumab-deruxtecan-302672228.htmlSOURCE Caris Life Sciences

Original: Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan

$CAI: IPOing today......... indicating $58 here

Was supposed to go for $21


Symbol: $CAI
Company: Caris Life Sciences, Inc.
Exchange: NASDAQ Global Select
Price: 19.00-20.00 USD
Shares: 23529412
Expected IPO Date: 2025-06-18
Offer Amount: $541,176,460.00

GO $CAI